NYSE · BSX
Healthcare · Medical - Devices
$43.87
Down-$1.18 (-2.62%)
Updated Sep 16, 2026, 9:52 AM
SID Score
4.9/10
Composite research score
Smart Money
74/100
Bullish
Price performance
1M range · 20 trading sessions · Daily adjusted prices
BSX closed at $43.87 after 20 trading sessions, down 13.08% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $44.32 | $44.9889 | $43.68 | $43.87 | 16.02M |
| Sep 14, 2026 | $44.00 | $45.15 | $43.85 | $45.05 | 20.52M |
| Sep 11, 2026 | $43.19 | $43.55 | $42.795 | $42.98 | 26.99M |
| Sep 10, 2026 | $44.13 | $44.42 | $42.78 | $43.10 | 22.69M |
| Sep 9, 2026 | $45.105 | $46.265 | $44.89 | $44.96 | 17.98M |
| Sep 8, 2026 | $47.43 | $47.45 | $44.85 | $44.98 | 29.03M |
| Sep 4, 2026 | $46.92 | $48.0583 | $46.83 | $47.80 | 15.5M |
| Sep 3, 2026 | $48.58 | $49.2656 | $46.80 | $46.95 | 19.73M |
| Sep 2, 2026 | $47.91 | $49.66 | $47.91 | $48.37 | 17.02M |
| Sep 1, 2026 | $49.115 | $49.115 | $47.27 | $48.08 | 12M |
| Aug 31, 2026 | $46.40 | $48.965 | $46.09 | $48.30 | 18.91M |
| Aug 28, 2026 | $46.85 | $47.22 | $46.50 | $46.84 | 17.15M |
| Aug 27, 2026 | $48.00 | $48.07 | $46.61 | $46.67 | 16.28M |
| Aug 26, 2026 | $47.00 | $48.54 | $46.90 | $48.17 | 36.58M |
| Aug 25, 2026 | $48.79 | $50.04 | $48.54 | $49.86 | 17.37M |
| Aug 24, 2026 | $50.29 | $50.38 | $48.77 | $49.01 | 22.03M |
| Aug 21, 2026 | $49.22 | $50.90 | $49.01 | $50.37 | 35.99M |
| Aug 20, 2026 | $51.64 | $51.80 | $49.36 | $49.37 | 20.39M |
| Aug 19, 2026 | $50.80 | $52.56 | $50.66 | $52.01 | 16.83M |
| Aug 18, 2026 | $52.38 | $52.53 | $50.45 | $50.47 | 11.72M |
The latest Smart Investors Daily articles mentioning BSX.
BSX research
Company profile and research snapshot.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | BTIG | Buy | — |
| Aug 25, 2026 | TD Cowen | Buy | — |
| Jul 31, 2026 | Argus Research | Hold | — |
| Jul 30, 2026 | Evercore ISI Group | Outperform | — |
| Jul 30, 2026 | Wells Fargo | Equal-Weight | — |
No generated briefing is available yet.
Yahoo · Sep 11, 2026
Boston Scientific (BSX) trades at about $43, roughly 17% below the recent high it set on 19th Aug, 2026. Its own history with sharp drops is encouraging. That history does not cover a cyberattack it says is likely to hit its 2026 results, and the stock is down about 60% over the past twelve months. Start with the history.
Yahoo · Sep 11, 2026
The average brokerage recommendation (ABR) for Boston Scientific (BSX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Yahoo · Sep 11, 2026
CEO Mike Mahoney gave more details at a Thursday investor conference, saying the company likely lost orders while its plants and distribution centers were shut down.
SeekingAlpha · Sep 11, 2026
Boston Scientific warns that the cyberattack will hit Q3, but recovery may delayânot loseârevenue. Click here to read this latest analysis of BSX stock.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BSX.
